{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T03:35:35Z","timestamp":1794281735328,"version":"4.9.0"},"reference-count":31,"publisher":"American Chemical Society (ACS)","issue":"2","license":[{"start":{"date-parts":[[2019,1,14]],"date-time":"2019-01-14T00:00:00Z","timestamp":1547424000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2019,1,14]],"date-time":"2019-01-14T00:00:00Z","timestamp":1547424000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2019,1,14]],"date-time":"2019-01-14T00:00:00Z","timestamp":1547424000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-045"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Chem. Res. Toxicol."],"published-print":{"date-parts":[[2019,2,18]]},"DOI":"10.1021\/acs.chemrestox.8b00313","type":"journal-article","created":{"date-parts":[[2019,1,14]],"date-time":"2019-01-14T15:50:09Z","timestamp":1547481009000},"page":"294-303","source":"Crossref","is-referenced-by-count":62,"title":["An Investigation into Retigabine (Ezogabine) Associated Dyspigmentation in Rat Eyes by MALDI Imaging Mass Spectrometry"],"prefix":"10.1021","volume":"32","author":[{"given":"M. Reid","family":"Groseclose","sequence":"first","affiliation":[{"name":"Department of Bioimaging, GlaxoSmithKline, 1250 S. Collegeville Road, Collegeville, Pennsylvania 19426, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9538-7057","authenticated-orcid":true,"given":"Stephen","family":"Castellino","sequence":"additional","affiliation":[{"name":"Department of Bioimaging, GlaxoSmithKline, 1250 S. Collegeville Road, Collegeville, Pennsylvania 19426, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2019,1,14]]},"reference":[{"key":"ref1\/cit1","doi-asserted-by":"publisher","DOI":"10.2147\/DHPS.S28814"},{"key":"ref2\/cit2","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(97)01249-1"},{"key":"ref3\/cit3","doi-asserted-by":"publisher","DOI":"10.1124\/mol.58.2.253"},{"key":"ref4\/cit4","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.21-15-05535.2001"},{"key":"ref5\/cit5","doi-asserted-by":"publisher","DOI":"10.1124\/mol.104.010793"},{"key":"ref6\/cit6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0150095"},{"key":"ref7\/cit7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1527-3458.2005.tb00033.x"},{"key":"ref8\/cit8","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S14208"},{"key":"ref9\/cit9","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1185"},{"key":"ref10\/cit10","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181fd6170"},{"key":"ref11\/cit11","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2012.03.010"},{"key":"ref12\/cit12","unstructured":"(2013) FDA Drug Safety Communication:\nAnti-seizure\ndrug Potiga (ezogabine) linked to retinal abnormalities and blue skin\ndiscoloration, FDA, Silver Spring, MD, http:\/\/wayback.archive-it.org\/7993\/20170112031636\/http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm349538.htm."},{"key":"ref13\/cit13","first-page":"96","volume":"55","year":"2013","journal-title":"Med. Lett. Drugs Ther."},{"key":"ref14\/cit14","doi-asserted-by":"publisher","DOI":"10.1097\/01.NAJ.0000432957.11010.12"},{"key":"ref15\/cit15","first-page":"269","volume":"22","year":"2013","journal-title":"Prescrire Int."},{"key":"ref16\/cit16","unstructured":"(2013) POTIGA (ezogabine) FDA Approved Labeling\ndated 09\/06\/2013, FDA, Silver Spring, MD."},{"key":"ref17\/cit17","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2013.8895"},{"key":"ref18\/cit18","doi-asserted-by":"publisher","DOI":"10.1186\/s12903-015-0102-y"},{"key":"ref19\/cit19","unstructured":"(2015) FDA Determines 2013\nlabeling adequate\nto manage risk of retinal abnormalities, potential vision loss, and\nskin discoloration with anti-seizure drug Potiga(ezogabine); requires\nadditional study,  FDA Safety Communication, FDA, Silver Spring,\nMD."},{"key":"ref20\/cit20","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.10-7020"},{"key":"ref21\/cit21","first-page":"613","volume":"27","author":"Hempel R.","year":"1999","journal-title":"Drug Metab. Dispos."},{"key":"ref22\/cit22","doi-asserted-by":"publisher","DOI":"10.1007\/s00204-016-1757-0"},{"key":"ref23\/cit23","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2017.12.008"},{"key":"ref24\/cit24","doi-asserted-by":"publisher","DOI":"10.1089\/jop.1992.8.35"},{"key":"ref25\/cit25","doi-asserted-by":"publisher","DOI":"10.1089\/jop.1986.2.385"},{"key":"ref26\/cit26","doi-asserted-by":"publisher","DOI":"10.3109\/03602532.2014.921190"},{"key":"ref27\/cit27","doi-asserted-by":"publisher","DOI":"10.1002\/jps.24680"},{"key":"ref28\/cit28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2017.07.027"},{"key":"ref29\/cit29","doi-asserted-by":"publisher","DOI":"10.1006\/rtph.1998.1243"},{"key":"ref30\/cit30","doi-asserted-by":"publisher","DOI":"10.1021\/cr0300688"},{"key":"ref31\/cit31","unstructured":"(2013) International Conference\non Harmonization\n(IHC) of technical requirements for registration of pharmaceuticals\nfor human use: photosafety evaluation of pharmaceuticals, IHC, Geneva, Switzerland, https:\/\/www.ich.org\/products\/guidelines\/safety\/article\/safety-guidelines.html (accessed December 17, 2018)."}],"container-title":["Chemical Research in Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.chemrestox.8b00313","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T21:10:11Z","timestamp":1681506611000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/doi\/10.1021\/acs.chemrestox.8b00313"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,14]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2,18]]}},"alternative-id":["10.1021\/acs.chemrestox.8b00313"],"URL":"https:\/\/doi.org\/10.1021\/acs.chemrestox.8b00313","relation":{"has-part":[{"id-type":"doi","id":"https:\/\/doi.org\/10.1021\/acs.chemrestox.8b00313.s001","asserted-by":"subject"}]},"ISSN":["0893-228X","1520-5010"],"issn-type":[{"value":"0893-228X","type":"print"},{"value":"1520-5010","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,14]]}}}